Biocon scores MYR 225 mn insulin supply deal in Malaysia
Duopharma Biotech's tender wins from Malaysia's MOH secure Biocon a three-drug supply agreement, but the annualized revenue is modest relative to its size.
What's new
- Duopharma Biotech won multiple insulin tenders from Malaysia's MOH totaling over MYR 225 mn.
- Biocon's Malaysian subsidiary to supply recombinant human insulin, insulin glargine, and insulin aspart.
- Contract durations: 3 years for human insulin (MYR 155.27 mn), 2 years each for glargine (MYR 18m) and aspart (MYR 52.5m).
Why this matters
The deal reinforces Biocon's decade-long presence in Malaysia's public healthcare insulin market, but the annualized revenue is only about 1.5% of its top line. For a ₹68,597 cr market cap company with trailing PAT down 56.8%, this order is too small to shift the growth trajectory.
What we're watching
- Execution ramp-up at the Johor facility.
- Any follow-on tenders in other ASEAN markets.
- Biocon's broader insulin strategy amid declining profitability.
The full read
Biocon's Malaysian arm secured insulin supply contracts worth over MYR 225 million via partner Duopharma Biotech's tender wins. The three deals cover human insulin (MYR 155.27 mn over 3 years), glargine (MYR 18 mn over 2 years), and aspart (MYR 52.5 mn over 2 years). The Johor facility will handle manufacturing. But the numbers are modest — annualised revenue is roughly 1.5% of Biocon's top line, and the company already has a strong presence in Malaysia. For a ₹68,597 cr market cap stock with a trailing P/E of 177.9 and 56.8% PAT decline, this contract won't change the narrative. It's a routine win in an existing relationship, not a breakout moment.
Questions answered
- What is the total contract value?
- Over MYR 225 million: MYR 155.27 million for human insulin (3 years), MYR 18 million for insulin glargine (2 years), and MYR 52.5 million for insulin aspart (2 years).
- Which products are included?
- Recombinant human insulin, insulin glargine, and insulin aspart.
- Where will the drugs be manufactured?
- At Biocon's Johor facility in Malaysia, which has attracted over USD 600 million in investment.
- How significant is this deal for Biocon's revenue?
- Modest — the annualised revenue is roughly 1.5% of Biocon's total revenue, which is over ₹10,000 crore.
- Is this a new partnership?
- No, Duopharma is a long-standing partner — Biocon has supplied over 120 million insulin cartridges to Malaysian public healthcare over the past decade.